Clinical trials: SARSCoV2 Convalescent Plasma
SARS-CoV-2 Infection
Plasma Therapy of COVID-19 in Severely Ill Patients
This randomized blinded multi-center phase 2 trial will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma among adults with severe COVID-19. Adults ≥18 years of age may participate.
- Trial name
- NCT04359810
- Testing
- Convalescent Plasma (anti-SARS-CoV-2 plasma), Non-convalescent Plasma (control plasma)
- Where
- 4 sites in United States, Brazil
- Volunteers
- 223 people
- Sponsor
- Max O'Donnell
COVID-19
Expanded Access to Convalescent Plasma for Treatment of COVID-19
This expanded access program will provide access to investigational convalescent plasma for patients at Hackensack University Medical Center infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged…
- Trial name
- NCT04472572
- Testing
- Convalescent Plasma
- Where
- United States
- Sponsor
- Hackensack Meridian Health
COVID-19
CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)
There is currently no treatment available for COVID-19, the acute respiratory illness caused by the novel SAR-CoV-2. Convalescent plasma from patients who have recovered from COVID-19 that contains antibodies to the virus is a…
- Trial name
- CONCOR-1 (NCT04348656)
- Testing
- Convalescent plasma
- Where
- 73 sites in United States, Brazil and 1 more
- Volunteers
- 940 people
- Sponsor
- Hamilton Health Sciences Corporation
COVID-19
COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.
The purpose of this study is to see if this plasma can be safely used in humans with COVID-19 and to see if it improves patients' health as compared to not using it in patients with pneumonia caused by SARS-CoV-2.
- Trial name
- NCT04397757
- Testing
- COVID-19 Convalescent Plasma
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Pennsylvania
COVID-19
Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study
Convalescent plasma has been shown to be safe and effective for treatment of several diseases. Preliminary data indicates that it is safe and effective for treatment of COVID.
- Trial name
- NCT04384497
- Testing
- SARS-CoV-2 convalescent plasma
- Where
- 2 sites in Sweden
- Volunteers
- 10 people
- Sponsor
- Joakim Dillner
SARS-CoV-2 Infection
Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)
The purpose of this study is to evaluate the safety of administration of plasma containing antibodies to the SARS-CoV-2 virus (i.e., convalescent plasma) and if it is able to prevent disease or lessen the severity of disease in…
- Trial name
- NCT04377672
- Testing
- Anti-SARS-CoV-2 Human Convalescent Plasma
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Johns Hopkins University
Corona Virus Infection
Covid-19 Convalescent Plasma as Prevention and Treatment for Children With Underlying Medical Conditions
This study will provide access to investigational anti-SARS-CoV-2 human convalescent plasma for pediatric patients with underlying medical conditions (cardiovascular disease, lung disease, immunosuppression) who are either…
- Trial name
- NCT04462848
- Testing
- anti-SARS-CoV-2 human convalescent plasma
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Los Angeles
COVID-19
Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection
This is a phase II randomized study of convalescent plasma for the treatment of non-immune individuals with COVID-19 infection at high risk of complications.
- Trial name
- NCT04456413
- Testing
- Convalescent Plasma, Best Supportive Care
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Hackensack Meridian Health
Sars-CoV2, Covid-19
Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected the global population with significant morbidity and mortality.
- Trial name
- NCT04425837
- Testing
- SARS-CoV-2 convalescent plasma treatment, Standard care
- Where
- Colombia
- Volunteers
- 236 people
- Sponsor
- Fundación Santa Fe de Bogota
COVID-19
Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection
This is a single arm phase IIa study of convalescent plasma for the treatment of individuals hospitalized with COVID-19 infection.
- Trial name
- NCT04343755
- Testing
- Convalescent Plasma
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Hackensack Meridian Health
COVID-19, Convalescent Plasma
Convalescent Plasma Therapy for Hospitalized Patients With COVID-19
Plasma from donors who have recovered from coronavirus disease 2019 (COVID-19) contain antibodies to SARS-CoV-2 and may be a potential therapy for hospitalized patients with COVID-19.
- Conditions
- COVID-19, Convalescent Plasma, SARS-CoV-2, Pneumonia
- Trial name
- NCT05077930
- Testing
- Convalescent plasma, Standard of care
- Where
- Brazil
- Volunteers
- 38 people
- Sponsor
- Tânia Portella Costa
Coronavirus
Convalescent Plasma to Limit Coronavirus Associated Complications
Researchers are trying to assess the treatment potential and safety of anti-SARS-CoV-2 convalescent plasma in patients with acute respiratory symptoms with confirmed COVID-19.
- Trial name
- NCT04325672
- Testing
- Convalescent Plasma
- Sponsor
- Mayo Clinic
SARS-CoV-2 Infection, Safety and Efficacy
Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients
This is a prospective, randomized (1:1), double blind study of Convalescent anti-SARS-CoV-2 MBT Plasma (also known as convalescent plasma) plus standard medical treatment (SMT) versus placebo plus SMT in mild or moderate COVID-19…
- Trial name
- NCT04621123
- Testing
- Convalescent anti-SARS-CoV-2 MBT plasma, Control Group
- Where
- 4 sites in Spain
- Volunteers
- 384 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
SARS Virus, SARS-CoV-2
Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia
A multicenter randomized, double-blind, placebo-controlled clinical trial of Convalescent SARS COVID-19 plasma versus Placebo to evaluate the effect between arms on an ordinal score of six mutually exclusive categories of…
- Conditions
- SARS Virus, SARS-CoV-2, COVID-19
- Trial name
- PLASM-AR (NCT04383535)
- Testing
- Convalescent SARS COVID-19 plasma
- Where
- Argentina
- Volunteers
- 333 people
- Sponsor
- Hospital Italiano de Buenos Aires
SARS Pneumonia
Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial
The new SARS-CoV-2 coronavirus is an emerging virus originating in Wuhan, China that has spread rapidly throughout the world. As of March 24, 2020, China had reported 81,767 cases with 3,281 deaths, and the World Health…
- Trial name
- CPC-SARS (NCT04405310)
- Testing
- Convalescent Plasma of patients with COVID-19
- Where
- 2 sites in Mexico
- Volunteers
- 42 people
- Sponsor
- Grupo Mexicano para el Estudio de la Medicina Intensiva
SARS-CoV-2 Infection, COVID-19 Infection
COVID-19 Convalescent Plasma Therapy
This study is an open-label trial in which hospitalized patients with risk factors of severe coronavirus disease 2019 [COVID-19] will be receive treatment with convalescent plasma (≤ 15 days from symptoms start).
- Trial name
- TPCC (NCT04747158)
- Testing
- Convalescent plasma
- Where
- Paraguay
- Volunteers
- 350 people
- Sponsor
- Universidad Nacional de Asunción
COVID19
Clinical Study for Efficacy of Anti-Corona VS2 Immunoglobulins Prepared From COVID19 Convalescent Plasma Prepared by VIPS Mini-Pool IVIG Medical Devices in Prevention of SARS-CoV-2 Infection in High Risk Groups as Well as Treatment of Early Cases of COVID19 Patients
Preparation of safe purified hyper immunoglobulins containing anti-Corona VS2 immunoglobulins from plasma collected from COVID19 convalescent patients to be used to: 1.
- Trial name
- NCT04383548
- Testing
- hyper immunoglobulins containing anti-Corona VS2 immunoglobulin
- Volunteers
- 100 people
- Sponsor
- Assiut University
SARS-Cov-2
Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19)
Convalescent plasma has been used for over 100 years in the treatment of severe acute respiratory infections of viral origin. There are not pharmacological treatments for the actual outbreak for SARS-Cov-2 and it is necessary to…
- Trial name
- NCT04391101
- Testing
- Convalescent plasma
- Where
- Colombia
- Volunteers
- 231 people
- Sponsor
- Hospital San Vicente Fundación
COVID-19
Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.
COVID-19 (Corona Virus Disease 2019) hospitalized patients evolution is marked by the risk of worsening of the respiratory system during the second week of the disease.
- Trial name
- PLASCOSSA (NCT04372979)
- Testing
- Transfusion of SARS-CoV-2 Convalescent Plasma., Transfusion of standard Plasma.
- Where
- 4 sites in France
- Volunteers
- 18 people
- Sponsor
- Direction Centrale du Service de Santé des Armées
COVID-19, Sars-CoV2
Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients
The purpose of this study assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms up to 14 days after the onset of initial symptoms.
- Trial name
- CAPRI (NCT04421404)
- Testing
- COVID-19 Convalescent Plasma (CCP)
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Priscilla Hsue, MD